Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
redePHine: ABO-101 in Primary Hyperoxaluria Type 1
NCT06839235Phase 2Recruiting
- Sponsor
- Arbor Biotechnologies
- Start
- Jun 2025
- Primary completion
- Mar 2029
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of ABO-101 in Primary Hyperoxaluria Type 1 (PH1) (2 arms), sponsored by Arbor Biotechnologies. Primary endpoint: Incidence and severity of treatment-emergent adverse events (TEAEs), including ABO-101-related TEAEs and serious adverse events (SAEs) at 6 months. Started Jun 2025; status: recruiting.
02
Drugs
ABO-101
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT06839235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839235.